<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01388543</url>
  </required_header>
  <id_info>
    <org_study_id>06-0428</org_study_id>
    <secondary_id>R03AI068438</secondary_id>
    <secondary_id>BMSV-338</secondary_id>
    <nct_id>NCT01388543</nct_id>
  </id_info>
  <brief_title>Genetics and HIV-1 Protease Inhibitors</brief_title>
  <official_title>Genetic-determinants of Protease Inhibitor Pharmacology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluated the blood levels of atazanavir according to a genetic makeup for CYP3A5
      (cytochrome P450 3A5, an enzyme that metabolizes atazanavir). The hypothesis was that people
      with a slow-metabolizing genotype would have higher blood levels of atazanavir compared to
      people with the normal metabolizing genotype.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug level Clearance and blood comparisons</measure>
    <time_frame>Day 7</time_frame>
    <description>Compare atazanavir oral clearance in genetically-determined CYP3A5 expressors versus CYP3A5 non-expressors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug level Clearance and blood comparisons</measure>
    <time_frame>Day 14</time_frame>
    <description>Characterize the effect of ritonavir boosting on atazanavir oral clearance in genetically-determined CYP3A5 expressors versus CYP3A5 non-expressors</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>CYP3A5 Expressors</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A pre-screening genetic test determines CYP3A5 expressor status</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CYP3A5 Non-expressors</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A pre-screening genetic test determines CYP3A5 non-expressor status</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir</intervention_name>
    <description>Atazanavir 400mg once daily for 7 days followed by atazanavir 300mg plus ritonavir 100mg for 7 days</description>
    <arm_group_label>CYP3A5 Expressors</arm_group_label>
    <arm_group_label>CYP3A5 Non-expressors</arm_group_label>
    <other_name>Reyataz</other_name>
    <other_name>Norvir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 55 years

          -  Negative HIV screening antibody test

          -  CYP3A5 expressor status, race, and sex fit an enrollment opening.

        Exclusion Criteria:

          -  Pregnant or breast-feeding

          -  Medical history of

               -  hepatitis B or C,

               -  autoimmune disease,

               -  active malignancy,

               -  kidney disease including nephrolithiasis

          -  Organ dysfunction manifested by

               -  liver transaminases or

               -  serum creatinine &gt;1.25 times the upper limit of normal, or

               -  any comprehensive metabolic test (except asymptomatic unconjugated
                  hyperbilirubinemia), blood count, or lipid value &gt; Grade I according to Division
                  of AIDS (DAIDS) adverse drug event grading system (appendix).

          -  Medical history of arrhythmias (including atrial fibrillation, atrioventricular block,
             and/or pacemaker)

          -  Any QT interval abnormalities or other congenital arrhythmia syndromes on ECG or

               -  Any ECG abnormality that in the opinion of the investigators would preclude entry
                  into the study.

          -  Medical history of any serious heart condition including:

               -  congestive heart failure,

               -  myopathies,

               -  coronary artery disease, or

               -  unexplained syncope.

          -  Medical history of bleeding disorders (i.e., hemophilia)

          -  Hyperlipidemia

          -  Any prescription, herbal, recreational, or over-the-counter medication contraindicated
             with ritonavir or atazanavir including:

               -  substrates/inhibitors/inducers of CYP3A/P-gp,

               -  cardio-active medication, or

               -  medications that alter the acid in the stomach. The study investigators will
                  review each concurrent medication on a case-by-case basis.

          -  Inability to refrain from grapefruit or grapefruit juice during the study.

          -  Investigational drugs within the last 30 days.

          -  Active alcohol / recreational drug abuse,

          -  Inability to give informed consent.

          -  A body mass index below 18.5 or above 34.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter L. Anderson, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado Denver and Health Sciences Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Denver and Health Sciences Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Anderson PL, Aquilante CL, Gardner EM, Predhomme J, McDaneld P, Bushman LR, Zheng JH, Ray M, MaWhinney S. Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors. J Antimicrob Chemother. 2009 Nov;64(5):1071-9. doi: 10.1093/jac/dkp317. Epub 2009 Aug 26.</citation>
    <PMID>19710077</PMID>
  </results_reference>
  <results_reference>
    <citation>Wempe MF, Anderson PL. Atazanavir metabolism according to CYP3A5 status: an in vitro-in vivo assessment. Drug Metab Dispos. 2011 Mar;39(3):522-7. doi: 10.1124/dmd.110.036178. Epub 2010 Dec 9.</citation>
    <PMID>21148251</PMID>
  </results_reference>
  <results_reference>
    <citation>Kile DA, MaWhinney S, Aquilante CL, Rower JE, Castillo-Mancilla JR, Anderson PL. A population pharmacokinetic-pharmacogenetic analysis of atazanavir. AIDS Res Hum Retroviruses. 2012 Oct;28(10):1227-34. Epub 2012 Apr 20.</citation>
    <PMID>22394315</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2011</study_first_submitted>
  <study_first_submitted_qc>July 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2011</study_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Clinical Pharmacology</keyword>
  <keyword>Pharmacogenomics</keyword>
  <keyword>HIV</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>HIV Protease Inhibitors</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to share</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

